281 related articles for article (PubMed ID: 33086064)
1. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
[TBL] [Abstract][Full Text] [Related]
2. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
[TBL] [Abstract][Full Text] [Related]
3. Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer.
Pan J; Hu Y; Sun S; Chen L; Schnaubelt M; Clark D; Ao M; Zhang Z; Chan D; Qian J; Zhang H
Nat Commun; 2020 Dec; 11(1):6139. PubMed ID: 33262351
[TBL] [Abstract][Full Text] [Related]
4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
5. An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.
Li QK; Shah P; Tian Y; Hu Y; Roden RBS; Zhang H; Chan DW
Clin Proteomics; 2017; 14():16. PubMed ID: 28491011
[TBL] [Abstract][Full Text] [Related]
6. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
[TBL] [Abstract][Full Text] [Related]
7. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
Huang D; Gaul DA; Nan H; Kim J; Fernández FM
J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
[TBL] [Abstract][Full Text] [Related]
8. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
[TBL] [Abstract][Full Text] [Related]
9. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
10. Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors.
Lanfredi GP; Thomé CH; Ferreira GA; Silvestrini VC; Masson AP; Vargas AP; Grassi ML; Poersch A; Candido Dos Reis FJ; Faça VM
Biochim Biophys Acta Proteins Proteom; 2021 Jun; 1869(6):140623. PubMed ID: 33607274
[TBL] [Abstract][Full Text] [Related]
11. A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Sheta R; Woo CM; Roux-Dalvai F; Fournier F; Bourassa S; Droit A; Bertozzi CR; Bachvarov D
J Proteomics; 2016 Aug; 145():91-102. PubMed ID: 27095597
[TBL] [Abstract][Full Text] [Related]
12. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
13. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
14. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
Wenk D; Khan S; Ignatchenko V; May T; Bernardini MQ; Kislinger T
J Proteome Res; 2024 Feb; 23(2):749-759. PubMed ID: 38266179
[TBL] [Abstract][Full Text] [Related]
15. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer.
Zhao Q; Laverdure JP; Lanoix J; Durette C; Côté C; Bonneil É; Laumont CM; Gendron P; Vincent K; Courcelles M; Lemieux S; Millar DG; Ohashi PS; Thibault P; Perreault C
Cancer Immunol Res; 2020 Apr; 8(4):544-555. PubMed ID: 32047025
[TBL] [Abstract][Full Text] [Related]
17. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
18. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids.
Kuzmanov U; Musrap N; Kosanam H; Smith CR; Batruch I; Dimitromanolakis A; Diamandis EP
Clin Chem Lab Med; 2013 Jul; 51(7):1467-76. PubMed ID: 23241603
[TBL] [Abstract][Full Text] [Related]
19. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
20. Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer.
Zhang G; Lu J; Yang M; Wang Y; Liu H; Xu C
Cancer Immunol Immunother; 2020 Feb; 69(2):175-187. PubMed ID: 31853576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
